JP2019508407A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019508407A5 JP2019508407A5 JP2018541178A JP2018541178A JP2019508407A5 JP 2019508407 A5 JP2019508407 A5 JP 2019508407A5 JP 2018541178 A JP2018541178 A JP 2018541178A JP 2018541178 A JP2018541178 A JP 2018541178A JP 2019508407 A5 JP2019508407 A5 JP 2019508407A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- halo
- disease
- attached
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 61
- 125000005843 halogen group Chemical group 0.000 claims 44
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 39
- 125000000623 heterocyclic group Chemical group 0.000 claims 38
- 125000004432 carbon atom Chemical group C* 0.000 claims 36
- 229910052799 carbon Inorganic materials 0.000 claims 35
- -1 difluoro (phenyl) methyl Chemical group 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 17
- 125000004093 cyano group Chemical group *C#N 0.000 claims 16
- 239000000651 prodrug Substances 0.000 claims 16
- 229940002612 prodrug Drugs 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 125000003107 substituted aryl group Chemical group 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 125000001153 fluoro group Chemical group F* 0.000 claims 7
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- LKYNGTHMKCTTQC-UHFFFAOYSA-N 1,2-oxazole-3-carboxamide Chemical compound NC(=O)C=1C=CON=1 LKYNGTHMKCTTQC-UHFFFAOYSA-N 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims 3
- 150000003852 triazoles Chemical class 0.000 claims 3
- 125000001425 triazolyl group Chemical group 0.000 claims 3
- QWEWLLNSJDTOKH-UHFFFAOYSA-N 1,3-thiazole-2-carboxamide Chemical compound NC(=O)C1=NC=CS1 QWEWLLNSJDTOKH-UHFFFAOYSA-N 0.000 claims 2
- PQQRHWFRZHFGFM-UHFFFAOYSA-N 1,3-thiazole-4-carboxamide Chemical compound NC(=O)C1=CSC=N1 PQQRHWFRZHFGFM-UHFFFAOYSA-N 0.000 claims 2
- RHQYWJCYKJYOHR-IBGZPJMESA-N 4-(2-amino-7-chloroquinolin-4-yl)-n-[(3s)-1-methyl-2-oxo-4,5-dihydro-3h-1-benzazepin-3-yl]piperazine-1-carboxamide Chemical compound O=C1N(C)C2=CC=CC=C2CC[C@@H]1NC(=O)N1CCN(C=2C3=CC=C(Cl)C=C3N=C(N)C=2)CC1 RHQYWJCYKJYOHR-IBGZPJMESA-N 0.000 claims 2
- GPXVGMFKVVCOPO-IBGZPJMESA-N 4-(2-amino-7-chloroquinolin-4-yl)-n-[(3s)-2-oxo-1,3,4,5-tetrahydro-1-benzazepin-3-yl]piperazine-1-carboxamide Chemical compound C1CC2=CC=CC=C2NC(=O)[C@H]1NC(=O)N(CC1)CCN1C1=C(C=CC(Cl)=C2)C2=NC(N)=C1 GPXVGMFKVVCOPO-IBGZPJMESA-N 0.000 claims 2
- LFTGCGDWACHEGE-UHFFFAOYSA-N 4-(2-oxo-1,4-dihydroquinazolin-3-yl)-n-(2-oxo-1-propan-2-yl-4,5-dihydro-3h-1-benzazepin-3-yl)piperidine-1-carboxamide Chemical compound O=C1N(C(C)C)C2=CC=CC=C2CCC1NC(=O)N1CCC(N2C(NC3=CC=CC=C3C2)=O)CC1 LFTGCGDWACHEGE-UHFFFAOYSA-N 0.000 claims 2
- 125000006281 4-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)C([H])([H])* 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 108010040003 polyglutamine Proteins 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- WXLCDTBTIVJDCE-UHFFFAOYSA-N 1,4-oxazepine Chemical compound O1C=CC=NC=C1 WXLCDTBTIVJDCE-UHFFFAOYSA-N 0.000 claims 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- SZEKQSIJYLHNSU-ZDUSSCGKSA-N 5-benzyl-N-[(3S)-8-fluoro-1-methyl-2-oxo-4,5-dihydro-3H-pyrido[2,3-b][1,4]diazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide Chemical compound CN1C2=CC(F)=CN=C2NC[C@H](NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C1=O SZEKQSIJYLHNSU-ZDUSSCGKSA-N 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 125000006414 CCl Chemical group ClC* 0.000 claims 1
- 108090000426 Caspase-1 Proteins 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000024412 Friedreich ataxia Diseases 0.000 claims 1
- 208000015872 Gaucher disease Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 208000028622 Immune thrombocytopenia Diseases 0.000 claims 1
- 208000028226 Krabbe disease Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000015439 Lysosomal storage disease Diseases 0.000 claims 1
- 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 claims 1
- 208000012583 Menkes disease Diseases 0.000 claims 1
- 208000014060 Niemann-Pick disease Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010038848 Retinal detachment Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000018839 Wilson disease Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 208000024557 hepatobiliary disease Diseases 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 1
- 230000001338 necrotic effect Effects 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920000155 polyglutamine Polymers 0.000 claims 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 230000004264 retinal detachment Effects 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 208000020408 systemic-onset juvenile idiopathic arthritis Diseases 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 0 *C([C@@](C=C)C1=C(N(*)C2=O)N=IC=C1)[C@@]2NC(C(/C=C/C=C1)=CC=CC=CC1=CI*)=O Chemical compound *C([C@@](C=C)C1=C(N(*)C2=O)N=IC=C1)[C@@]2NC(C(/C=C/C=C1)=CC=CC=CC1=CI*)=O 0.000 description 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021179107A JP7381543B2 (ja) | 2016-02-05 | 2021-11-02 | 化合物、組成物及び方法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662292202P | 2016-02-05 | 2016-02-05 | |
| US62/292,202 | 2016-02-05 | ||
| US201662341019P | 2016-05-24 | 2016-05-24 | |
| US62/341,019 | 2016-05-24 | ||
| US201662363775P | 2016-07-18 | 2016-07-18 | |
| US62/363,775 | 2016-07-18 | ||
| US201662385217P | 2016-09-08 | 2016-09-08 | |
| US62/385,217 | 2016-09-08 | ||
| US201662417219P | 2016-11-03 | 2016-11-03 | |
| US62/417,219 | 2016-11-03 | ||
| PCT/US2017/016509 WO2017136727A2 (en) | 2016-02-05 | 2017-02-03 | Compounds, compositions and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021179107A Division JP7381543B2 (ja) | 2016-02-05 | 2021-11-02 | 化合物、組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019508407A JP2019508407A (ja) | 2019-03-28 |
| JP2019508407A5 true JP2019508407A5 (enExample) | 2020-03-12 |
| JP6974331B2 JP6974331B2 (ja) | 2021-12-01 |
Family
ID=58054535
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018541178A Active JP6974331B2 (ja) | 2016-02-05 | 2017-02-03 | 化合物、組成物及び方法 |
| JP2021179107A Active JP7381543B2 (ja) | 2016-02-05 | 2021-11-02 | 化合物、組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021179107A Active JP7381543B2 (ja) | 2016-02-05 | 2021-11-02 | 化合物、組成物及び方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (8) | US9815850B2 (enExample) |
| EP (1) | EP3414239A2 (enExample) |
| JP (2) | JP6974331B2 (enExample) |
| KR (1) | KR102808827B1 (enExample) |
| CN (4) | CN118994191A (enExample) |
| AU (1) | AU2017213628B2 (enExample) |
| CA (1) | CA3012832A1 (enExample) |
| CL (1) | CL2018002081A1 (enExample) |
| CO (1) | CO2018008707A2 (enExample) |
| CR (1) | CR20180413A (enExample) |
| DO (1) | DOP2018000175A (enExample) |
| EA (1) | EA201891620A1 (enExample) |
| EC (1) | ECSP18066138A (enExample) |
| IL (2) | IL287136B2 (enExample) |
| MA (1) | MA44007A (enExample) |
| MX (3) | MX2018009448A (enExample) |
| MY (1) | MY196648A (enExample) |
| PE (1) | PE20181665A1 (enExample) |
| PH (1) | PH12018501583A1 (enExample) |
| SA (1) | SA518392146B1 (enExample) |
| SG (2) | SG11201806302RA (enExample) |
| TN (1) | TN2018000276A1 (enExample) |
| TW (2) | TWI781920B (enExample) |
| WO (1) | WO2017136727A2 (enExample) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI648274B (zh) | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 （二） |
| RU2716136C2 (ru) | 2015-07-02 | 2020-03-06 | Ф. Хоффманн-Ля Рош Аг | Бициклические лактамы и способы их применения |
| MY197231A (en) | 2015-07-22 | 2023-06-06 | Enanta Pharm Inc | Benzodiazepine derivatives as rsv inhibitors |
| US10961258B2 (en) | 2015-12-21 | 2021-03-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| CN108699077B (zh) | 2016-01-15 | 2021-03-02 | 英安塔制药有限公司 | 作为rsv抑制剂的杂环化合物 |
| US9815850B2 (en) * | 2016-02-05 | 2017-11-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| TWI759301B (zh) | 2016-05-24 | 2022-04-01 | 美商安美基公司 | 聚乙二醇化卡非佐米化合物 |
| PT3472153T (pt) * | 2016-06-16 | 2021-12-31 | Denali Therapeutics Inc | Pirimidin-2-ilamino-1h-pirazóis como inibidores de lrrk2 para uso no tratamento de distúrbios neurodegenerativos |
| JP7349359B2 (ja) | 2016-10-17 | 2023-09-22 | エフ． ホフマン－ラ ロシュ アーゲー | 二環式ピリドンラクタム及びその使用方法。 |
| US11071721B2 (en) | 2016-12-02 | 2021-07-27 | Genentech, Inc. | Bicyclic amide compounds and methods of use thereof |
| US11072607B2 (en) * | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| WO2018152413A1 (en) | 2017-02-16 | 2018-08-23 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of benzodiazepine derivatives |
| EP3585782A1 (en) | 2017-02-27 | 2020-01-01 | GlaxoSmithKline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| WO2018226801A1 (en) | 2017-06-07 | 2018-12-13 | Enanta Pharmaceuticals, Inc. | Aryldiazepine derivatives as rsv inhibitors |
| US10851115B2 (en) | 2017-06-30 | 2020-12-01 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
| WO2019006295A1 (en) | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS |
| CN119613408A (zh) | 2017-07-14 | 2025-03-14 | 豪夫迈·罗氏有限公司 | 二环酮化合物及其使用方法 |
| CN107759574B (zh) * | 2017-08-29 | 2020-07-03 | 南京药石科技股份有限公司 | 一种5-氟-1h-吡唑-3-甲酸酯中间体及其合成方法 |
| CN111386118B (zh) | 2017-09-29 | 2023-05-09 | 英安塔制药有限公司 | 作为rsv抑制剂的组合药物剂 |
| WO2019072942A1 (en) * | 2017-10-11 | 2019-04-18 | F. Hoffmann-La Roche Ag | BICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF KINASE RIP1 |
| MX2020003451A (es) * | 2017-10-31 | 2020-08-03 | Hoffmann La Roche | Sulfonas y sulfoxidos biciclicos y metodos de uso de los mismos. |
| MX394621B (es) | 2017-11-13 | 2025-03-24 | Enanta Pharm Inc | Procesos para la resolucion de los derivados de la benzodiazepina-2-ona y de la benzoazepin-2-ona |
| WO2019094920A1 (en) * | 2017-11-13 | 2019-05-16 | Enanta Pharmaceuticals, Inc. | Azepin-2-one derivatives as rsv inhibitors |
| CN108129288B (zh) * | 2017-12-27 | 2021-01-22 | 上海毕得医药科技股份有限公司 | 一种反式-3-羟基环丁基甲酸的合成方法 |
| WO2019199908A1 (en) | 2018-04-11 | 2019-10-17 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as rsv inhibitors |
| EP3781571B1 (en) | 2018-04-20 | 2024-01-17 | F. Hoffmann-La Roche AG | N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
| SI3788044T1 (sl) * | 2018-05-03 | 2023-12-29 | Rigel Pharmaceuticals, Inc. | Spojine, ki zavirajo RIP1 in postopki za njihovo izdelavo in uporabo |
| PL3788045T3 (pl) * | 2018-05-03 | 2023-10-09 | Rigel Pharmaceuticals, Inc. | Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystania |
| WO2020001420A1 (zh) * | 2018-06-26 | 2020-01-02 | 中国科学院上海有机化学研究所 | 一类细胞坏死抑制剂及其制备方法和用途 |
| WO2020044206A1 (en) | 2018-08-29 | 2020-03-05 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors for use in the treatment cancer |
| WO2020054657A1 (ja) * | 2018-09-10 | 2020-03-19 | 科研製薬株式会社 | 新規ヘテロ芳香族アミド誘導体及びそれを含有する医薬 |
| CN111138448B (zh) * | 2018-11-02 | 2022-08-02 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
| JP7045526B2 (ja) * | 2018-11-02 | 2022-03-31 | 中国科学院上海薬物研究所 | Ｒｉｐ１キナーゼを阻害する複素環状アミド及びその使用 |
| BR112021009610A2 (pt) | 2018-11-20 | 2021-08-10 | Sironax Ltd | composto, composição farmacêutica, uso de um composto ou composição, e, método de inibir necrose, ferroptose, rip1 humana ou indicações relacionadas |
| EP3670667A1 (en) * | 2018-12-19 | 2020-06-24 | Paris Sciences et Lettres - Quartier Latin | Identification of cognate pairs of ligands and receptors |
| CN113302193B (zh) | 2019-01-11 | 2026-05-29 | 豪夫迈·罗氏有限公司 | 双环吡咯并三唑酮化合物及其使用方法 |
| CA3127701C (en) * | 2019-01-25 | 2023-08-15 | Beijing Scitech-Mq Pharmaceuticals Limited | Acylamino bridged heterocyclic compound, and composition and application thereof |
| WO2020190935A1 (en) | 2019-03-18 | 2020-09-24 | Enanta Pharmaceuticals, Inc. | Benzodiazepine derivatives as rsv inhibitors |
| US11179400B2 (en) | 2019-04-09 | 2021-11-23 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
| CA3142360C (en) * | 2019-05-31 | 2023-11-14 | Medshine Discovery Inc. | Bicyclic compound as rip-1 kinase inhibitor and application thereof |
| CN110172068A (zh) * | 2019-06-05 | 2019-08-27 | 河南龙湖生物技术有限公司 | 具有抗肿瘤活性的苯并噻唑类化合物及其制备方法和应用 |
| US12365695B2 (en) * | 2019-08-09 | 2025-07-22 | Bisichem Co., Ltd. | Fused ring heteroaryl compounds as RIPK1 inhibitors |
| AU2020341708B2 (en) | 2019-09-06 | 2024-01-04 | Rigel Pharmaceuticals, Inc. | RIP1 inhibitory compounds and methods for making and using the same |
| ES3043457T3 (en) * | 2019-09-06 | 2025-11-25 | Rigel Pharmaceuticals Inc | Rip1 inhibitory compounds and methods for making and using the same |
| US11718612B2 (en) | 2019-09-06 | 2023-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase I for the treatment of disease |
| WO2021050672A1 (en) * | 2019-09-11 | 2021-03-18 | Ohio State Innovation Foundation | Kinase inhibitors for the treatment of neurodegenerative diseases |
| IL291665B2 (en) | 2019-09-27 | 2025-07-01 | Univ Texas | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| PH12022550783A1 (en) | 2019-10-04 | 2023-07-31 | Enanta Pharm Inc | Antiviral heterocyclic compounds |
| SMT202600151T1 (it) * | 2019-11-07 | 2026-05-12 | Rigel Pharmaceuticals Inc | Composti eterociclici inibitori di rip1 |
| AU2020391425A1 (en) * | 2019-11-26 | 2022-06-16 | Board Of Regents, The University Of Texas System | Inhibitors of Receptor Interacting Protein Kinase 1 for the treatment of disease |
| UY39032A (es) | 2020-01-24 | 2021-07-30 | Enanta Pharm Inc | Compuestos heterocíclicos como agentes antivirales |
| BR112022017099A2 (pt) | 2020-02-28 | 2022-11-16 | Univ Texas | Composto, composição farmacêutica, método para inibição de ripk1, método para tratamento de uma doença mediada por ripk1 e método para tratamento de lesão no snc |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| CA3173330A1 (en) * | 2020-04-17 | 2021-10-21 | Genzyme Corporation | Eclitasertib for use in treating conditions involving systemichyperinflammatory response |
| TW202214617A (zh) | 2020-06-02 | 2022-04-16 | 法商賽諾菲公司 | 作為ｒｉｐｋ１抑制劑之異㗁唑啶及其用途 |
| TWI824259B (zh) * | 2020-07-01 | 2023-12-01 | 美商雷傑製藥公司 | Rip1k抑制劑 |
| WO2022010882A1 (en) | 2020-07-07 | 2022-01-13 | Enanta Pharmaceuticals, Inc, | Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors |
| WO2022086840A1 (en) | 2020-10-19 | 2022-04-28 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as anti-viral agents |
| WO2022109360A1 (en) | 2020-11-23 | 2022-05-27 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| CN114716427B (zh) * | 2021-01-07 | 2024-04-26 | 成都贝诺科成生物科技有限公司 | 一种作为rip抑制剂的化合物及其制备方法和用途 |
| WO2022171110A1 (en) * | 2021-02-10 | 2022-08-18 | Zai Lab (Us) Llc | Fused tricyclic compounds as rip1-kinase inhibitors and uses thereof |
| WO2022171111A1 (en) * | 2021-02-10 | 2022-08-18 | Zai Lab (Us) Llc | Heteroaryl-fused bicyclic compound as rip1-kinase inhibitors and uses thereof |
| US12612412B2 (en) | 2021-02-26 | 2026-04-28 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| MX2023009961A (es) | 2021-02-26 | 2023-09-05 | Enanta Pharm Inc | Compuestos heterociclicos antivirales. |
| TW202300490A (zh) | 2021-03-11 | 2023-01-01 | 美商雷傑製藥公司 | 雜環rip1激酶抑制劑 |
| JP7651929B2 (ja) | 2021-04-19 | 2025-03-27 | 住友ゴム工業株式会社 | ゴム組成物及びタイヤ |
| US11970502B2 (en) | 2021-05-04 | 2024-04-30 | Enanta Pharmaceuticals, Inc. | Macrocyclic antiviral agents |
| CN114989156B (zh) * | 2021-05-19 | 2024-07-05 | 成都贝诺科成生物科技有限公司 | 一种受体相互作用蛋白抑制剂及其制备方法和用途 |
| TW202321211A (zh) | 2021-08-10 | 2023-06-01 | 美商艾伯維有限公司 | 菸鹼醯胺ripk1抑制劑 |
| KR20240099181A (ko) * | 2021-09-17 | 2024-06-28 | 주식회사 비씨켐 | Ripk1 저해제로서 융합된 이종환식 고리 |
| CN118510775A (zh) | 2021-11-11 | 2024-08-16 | 建新公司 | 作为ripk1抑制剂的异噁唑烷及其用途 |
| WO2023086352A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| US11858945B2 (en) | 2021-11-12 | 2024-01-02 | Enanta Pharmaceuticals, Inc. | Alkyne-containing antiviral agents |
| WO2023086400A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| US11993600B2 (en) | 2021-12-08 | 2024-05-28 | Enanta Pharmaceuticals, Inc. | Saturated spirocyclics as antiviral agents |
| KR20230100646A (ko) | 2021-12-24 | 2023-07-05 | 제일약품주식회사 | Ripk1 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
| EP4209213A1 (en) | 2022-01-05 | 2023-07-12 | Universität zu Köln | Signalling-pathway inhibitor combinations for use in the treatment of cancer diseases |
| US12006291B2 (en) | 2022-01-11 | 2024-06-11 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of 4,6,7-trifluoro-1H-indole-2-carboxylic acid |
| EP4463229A1 (en) * | 2022-01-12 | 2024-11-20 | Denali Therapeutics Inc. | Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide |
| CN116640156B (zh) * | 2022-02-22 | 2025-10-24 | 上海齐鲁制药研究中心有限公司 | Ripk1抑制剂 |
| EP4495119A4 (en) | 2022-03-16 | 2025-06-25 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD AND MEDICAL USE THEREOF |
| US12145942B2 (en) | 2022-04-05 | 2024-11-19 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| AR129003A1 (es) | 2022-04-07 | 2024-07-03 | Enanta Pharm Inc | Compuestos heterocíclicos antivirales |
| WO2023211997A1 (en) | 2022-04-27 | 2023-11-02 | Enanta Pharmaceuticals, Inc. | Antiviral compounds |
| WO2024170776A1 (en) | 2023-02-17 | 2024-08-22 | Universität Zu Köln | Triple kinase inhibition for the treatment of type i interferon response associated disorders |
| KR20260074423A (ko) * | 2023-08-16 | 2026-05-22 | 주식회사 비씨켐 | Rip1 키나아제 억제제로서의 피라졸-1-카르복스아미드 |
| WO2025045253A1 (zh) * | 2023-08-31 | 2025-03-06 | 杭州百诚医药科技股份有限公司 | 苯并氮杂䓬酮类衍生物及其用途 |
| CN118084889B (zh) * | 2024-01-16 | 2024-09-27 | 宁夏医科大学 | 吲哚3-芳基-5-甲酰胺类衍生物及用途 |
| CN117849327A (zh) * | 2024-03-06 | 2024-04-09 | 军科正源（北京）药物研究有限责任公司 | 用于检测苏金单抗抗药性抗体的方法 |
| EP4652998A1 (en) | 2024-05-21 | 2025-11-26 | Technische Universität München | Treatment of receptor-interacting protein kinase 1- mediated disease with eclitasertib |
| WO2026006589A1 (en) | 2024-06-27 | 2026-01-02 | Genzyme Corporation | Eclitasertib for treating receptor-interacting protein kinase 1 -mediated diseases |
| WO2026085124A1 (en) * | 2024-10-15 | 2026-04-23 | Genzyme Corporation | Process for preparing (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5- tetrahydropyrido[3,2-b][l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3- carboxamide |
| WO2026138869A1 (zh) * | 2024-12-26 | 2026-07-02 | 津药药业股份有限公司 | Ripk1抑制剂及其用途 |
Family Cites Families (173)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6204261B1 (en) | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
| US4477464A (en) | 1983-02-10 | 1984-10-16 | Ciba-Geigy Corporation | Hetero-benzazepine derivatives and their pharmaceutical use |
| EP0187037A3 (en) | 1984-12-21 | 1988-03-23 | Takeda Chemical Industries, Ltd. | Piperidine derivatives, their production and use |
| JPH035933Y2 (enExample) | 1987-08-04 | 1991-02-15 | ||
| EP0322779A3 (en) | 1987-12-29 | 1991-05-08 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzolactam compounds and pharmaceutical uses thereof |
| JPH0256318A (ja) | 1988-08-19 | 1990-02-26 | Fujio Asai | 丸棒材の繰出しケース |
| JPH0295996A (ja) | 1988-10-03 | 1990-04-06 | Honda Motor Co Ltd | 鞍乗型車両 |
| JPH0334977A (ja) | 1989-06-29 | 1991-02-14 | Yoshitomi Pharmaceut Ind Ltd | イミダゾリルベンゾラクタム化合物 |
| NZ238576A (en) | 1990-06-18 | 1994-12-22 | Merck & Co Inc | Pyridinone derivatives, preparation and pharmaceutical compositions thereof |
| EP0481614A1 (en) | 1990-10-01 | 1992-04-22 | Merck & Co. Inc. | Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists |
| US5206234A (en) | 1990-10-22 | 1993-04-27 | Merck & Co., Inc. | Benzolactam analogs as antagonists of cck |
| US5206235A (en) | 1991-03-20 | 1993-04-27 | Merck & Co., Inc. | Benzo-fused lactams that promote the release of growth hormone |
| CA2078758C (en) | 1991-09-27 | 2003-12-09 | Alan M. Warshawsky | 2-substituted indane-2-mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace |
| US5457196A (en) | 1991-09-27 | 1995-10-10 | Merrell Dow Pharmaceuticals Inc. | 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE |
| JP3358069B2 (ja) | 1991-12-24 | 2002-12-16 | 武田薬品工業株式会社 | 三環性複素環類、その製造法及び剤 |
| US5484917A (en) | 1993-06-16 | 1996-01-16 | Pfizer Inc. | Substituted tetrahydrobenzazepinones |
| JP2655754B2 (ja) | 1992-07-01 | 1997-09-24 | フアイザー・インコーポレイテツド | コレシストキニンレセプター拮抗剤としてのベンゾチアゼピン及びベンゾオキサゼピンの誘導体 |
| US5420271A (en) | 1992-08-24 | 1995-05-30 | Merrell Dow Pharmaceuticals, Inc. | 2-substituted indane-2-mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase |
| JP3427937B2 (ja) | 1992-08-24 | 2003-07-22 | メレルダウファ−マス−ティカルズ インコーポレイテッド | エンケファリナーゼ阻害剤として有用な新規な２‐置換インダン‐２‐メルカプトアセチルアミド三環式誘導体類 |
| US5283241A (en) | 1992-08-28 | 1994-02-01 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
| JPH07501085A (ja) | 1992-09-03 | 1995-02-02 | ベーリンガー インゲルハイム コマンディトゲゼルシャフト | 新規なアミノ酸誘導体、その製造方法及びこれらの化合物を含む医薬組成物 |
| US5583130A (en) | 1992-09-25 | 1996-12-10 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
| US5317017A (en) | 1992-09-30 | 1994-05-31 | Merck & Co., Inc. | N-biphenyl-3-amido substituted benzolactams stimulate growth hormone release |
| US5374721A (en) | 1992-10-14 | 1994-12-20 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
| EP0619751B1 (en) | 1992-10-16 | 2003-05-07 | Suprex Corporation | Automated supercritical fluid extraction |
| GB2272439A (en) | 1992-11-13 | 1994-05-18 | Merck & Co Inc | Benzo-fused lactams that inhibit the release of growth hormone |
| US5284841A (en) | 1993-02-04 | 1994-02-08 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
| GB9307833D0 (en) | 1993-04-15 | 1993-06-02 | Glaxo Inc | Modulators of cholecystokinin and gastrin |
| WO1994026718A1 (fr) | 1993-05-13 | 1994-11-24 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose de 3-aminoazepine et son utilisation pharmaceutique |
| US5430144A (en) | 1993-07-26 | 1995-07-04 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
| ES2081747B1 (es) | 1993-09-07 | 1997-01-16 | Esteve Labor Dr | Amidas derivadas de tienopirroles, su preparacion y su aplicacion como medicamentos. |
| US5606054A (en) | 1993-12-14 | 1997-02-25 | Merck & Co., Inc. | Heterocyclic-fused lactams promote release of growth hormone |
| SK281433B6 (sk) | 1994-04-14 | 2001-03-12 | Glaxo Wellcome Inc. | 5-heterocyklo-1,5-benzodiazepínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie |
| MX9605128A (es) | 1994-05-07 | 1997-08-30 | Boehringer Ingelheim Kg | Nuevos derivados de aminoacidos, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos. |
| IL114955A (en) | 1994-08-17 | 1999-12-22 | Novo Nordisk As | N-substituted naphthofused lactams and pharmaceutical compositions containing them |
| GB9420747D0 (en) | 1994-10-14 | 1994-11-30 | Glaxo Inc | 1,5 benzodiazepine derivatives |
| GB9420748D0 (en) | 1994-10-14 | 1994-11-30 | Glaxo Inc | 1,5 benzodiazepine derivatives |
| GB9420763D0 (en) | 1994-10-14 | 1994-11-30 | Glaxo Inc | Acetamide derivatives |
| JPH10509453A (ja) | 1994-11-17 | 1998-09-14 | チバ スペシャルティ ケミカルズ ホールディング インコーポレーテッド | 架橋可能なモノマーおよび組成物、および架橋されたポリマー |
| US5587375A (en) | 1995-02-17 | 1996-12-24 | Bristol-Myers Squibb Company | Azepinone compounds useful in the inhibition of ACE and NEP |
| ATE235472T1 (de) | 1995-06-07 | 2003-04-15 | Merck & Co Inc | N-(2-oxo-2,3,4,5-tetrahydro-1h-1,5-benzodiazepi - 3-yl)-3-amide |
| US5700797A (en) | 1995-06-07 | 1997-12-23 | Merck & Co, Inc. | N-(2,4-dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3-yl)-3-amides |
| US5691331A (en) | 1995-06-07 | 1997-11-25 | Merck & Co., Inc. | N-(2,4-Dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3yl) -3- amides |
| US5726171A (en) | 1995-06-07 | 1998-03-10 | Merck & Co Inc | N-(1-alkyl-5-phenyl-2,3,4,5-tetrahydro-1H-benzo B! 1,4!diazepin-3yl)-acetamides |
| EP0761680A3 (en) | 1995-09-12 | 1999-05-06 | Ono Pharmaceutical Co., Ltd. | Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity |
| SI0850235T1 (en) | 1995-09-15 | 2000-04-30 | Sanofi-Synthelabo | Quinolein-2(1h)-one derivatives as serotonin antagonists |
| WO1997024339A1 (en) | 1995-12-27 | 1997-07-10 | Ono Pharmaceutical Co., Ltd. | Tetrazole derivatives and drugs containing the same as the active ingredient |
| US5747235A (en) | 1996-01-26 | 1998-05-05 | Eastman Kodak Company | Silver halide light sensitive emulsion layer having enhanced photographic sensitivity |
| JPH09295996A (ja) | 1996-03-06 | 1997-11-18 | Takeda Chem Ind Ltd | システインプロテアーゼ阻害化合物 |
| EP0850222B1 (en) | 1996-06-29 | 2003-05-28 | Samjin Pharmaceutical Co., Ltd. | Piperazine derivatives and process for the preparation thereof |
| DE19638020A1 (de) | 1996-09-18 | 1998-03-19 | Solvay Pharm Gmbh | Die gastrointestinale Durchblutung fördernde Arzneimittel |
| JP4094066B2 (ja) | 1996-12-06 | 2008-06-04 | バーテックス ファーマシューティカルズ インコーポレイテッド | インターロイキン−１β変換酵素のインヒビター |
| JPH10251295A (ja) | 1997-03-07 | 1998-09-22 | Ono Pharmaceut Co Ltd | テトラゾール誘導体 |
| WO1999007731A1 (en) | 1997-08-11 | 1999-02-18 | Cor Therapeutics, Inc. | SELECTIVE FACTOR Xa INHIBITORS |
| US6211174B1 (en) | 1997-10-31 | 2001-04-03 | Merck & Co., Inc. | Naphtho-fused lactams promote release of growth hormone |
| FR2781483A1 (fr) | 1998-07-21 | 2000-01-28 | Hoechst Marion Roussel Inc | Derives de thioazepinone, procede de preparation et intermediaires de ce procede, application a titre de medicament et compositions pharmaceutiques les renfermant |
| DE19858253A1 (de) | 1998-12-17 | 2000-06-21 | Aventis Pharma Gmbh | Verwendung von Inhibitoren des KQt1-Kanals zur Herstellung eines Medikaments zur Behandlung von Krankheiten, die durch Helminthen und Ektoparasiten hervorgerufen werden |
| JP2000256318A (ja) | 1999-03-02 | 2000-09-19 | Toa Eiyo Ltd | 縮合複素環誘導体、その製造法およびそれを含有する医薬品 |
| FR2803594B1 (fr) | 2000-01-11 | 2002-07-19 | Centre Nat Rech Scient | Oligomeres de mimes contraints non peptidiques de dipeptides ou de tripeptides, et leurs utilisations |
| EP1268434A1 (en) | 2000-04-03 | 2003-01-02 | Bristol-Myers Squibb Pharma Company | Cyclic lactams as inhibitors of a-beta protein production |
| MXPA02009755A (es) | 2000-04-03 | 2003-03-27 | Bristol Myers Squibb Pharma Co | Lactamas ciclicas como inhibidores de la produccion de proteina a-beta. |
| WO2001079261A1 (en) | 2000-04-14 | 2001-10-25 | Corvas International, Inc. | Tetrahydro-azepinone derivatives as thrombin inhibitors |
| ATE472539T1 (de) | 2000-04-24 | 2010-07-15 | Vertex Pharma | Verfahren und zwischenprodukte zur herstellung von substituierten asparaginsäure-acetalen |
| GB0012671D0 (en) | 2000-05-24 | 2000-07-19 | Merck Sharp & Dohme | Therapeutic agents |
| IL147629A0 (en) | 2000-06-01 | 2002-08-14 | Bristol Myers Squibb Pharma Co | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
| AUPQ969800A0 (en) | 2000-08-28 | 2000-09-21 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyridine compound and pharmaceutical use thereof |
| WO2002020500A2 (en) | 2000-09-01 | 2002-03-14 | Icos Corporation | Materials and methods to potentiate cancer treatment |
| GB0021831D0 (en) * | 2000-09-06 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| CA2448737C (en) | 2001-07-20 | 2010-06-01 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
| US7294457B2 (en) | 2001-08-07 | 2007-11-13 | Boehringer Ingelheim (Canada) Ltd. | Direct binding assay for identifying inhibitors of HCV polymerase |
| WO2003031376A1 (en) | 2001-10-12 | 2003-04-17 | Aventis Pharmaceuticals Inc. | Solid phase synthesis of substituted 1,5-benzodiazepine-2-one and 1,5-benzothiazepine-2-one |
| US7057046B2 (en) | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
| CA2489560A1 (en) * | 2002-06-27 | 2004-01-08 | Schering Aktiengesellschaft | Substituted quinoline ccr5 receptor antagonists |
| US7098235B2 (en) | 2002-11-14 | 2006-08-29 | Bristol-Myers Squibb Co. | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds |
| WO2004055008A1 (en) | 2002-12-13 | 2004-07-01 | Smithkline Beecham Corporation | Compounds, compositions and methods |
| US7288559B2 (en) | 2003-03-14 | 2007-10-30 | Merck + Co, Inc. | Carboxamide spirohydantoin CGRP receptor antagonists |
| ATE410161T1 (de) | 2003-05-02 | 2008-10-15 | Elan Pharm Inc | 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen |
| JP2005035933A (ja) | 2003-07-15 | 2005-02-10 | Takeda Chem Ind Ltd | 含窒素縮合複素環化合物の製造方法 |
| AU2004315596B2 (en) | 2003-08-29 | 2011-11-24 | President And Fellows Of Harvard College | Inhibitors of cellular necrosis |
| NZ546663A (en) | 2003-10-10 | 2010-01-29 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| WO2005056577A2 (en) | 2003-12-05 | 2005-06-23 | The Regents Of The University Of California | Peptide inhibitors of hiv |
| US20070010428A1 (en) | 2004-09-03 | 2007-01-11 | Mcmurray John S | Inhibitors of signal transduction and activator of transcription 3 |
| US7390798B2 (en) | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
| EP1802637B1 (en) * | 2004-10-13 | 2008-10-15 | Merck & Co., Inc. | Cgrp receptor antagonists |
| DE602005027870D1 (de) | 2004-10-14 | 2011-06-16 | Merck Sharp & Dohme | Cgrp-rezeptorantagonisten |
| ATE424821T1 (de) | 2004-12-02 | 2009-03-15 | Prosidion Ltd | Pyrrolopyridin-2-karbonsäureamide |
| US7875627B2 (en) | 2004-12-07 | 2011-01-25 | Abbott Laboratories | Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof |
| US20060217362A1 (en) | 2004-12-29 | 2006-09-28 | Tung Jay S | Novel compounds useful for bradykinin B1 receptor antagonism |
| WO2006079077A2 (en) | 2005-01-20 | 2006-07-27 | Acadia Pharmaceuticals Inc. | Use of diltiazem or analogs thereof as modulators of ghrelin receptor |
| US20060281763A1 (en) | 2005-03-25 | 2006-12-14 | Axon Jonathan R | Carboxamide inhibitors of TGFbeta |
| EA200701856A1 (ru) | 2005-04-01 | 2008-02-28 | Уорнер-Ламберт Компани Ллс | Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении |
| WO2006113432A2 (en) | 2005-04-14 | 2006-10-26 | Smithkline Beecham Corporation | Compounds, compositions and methods |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| BRPI0616338A2 (pt) | 2005-09-23 | 2011-06-14 | Coley Pharm Group Inc | mÉtodo para 1h-imidazo[4,5-c] piridinas e anÁlogos da mesma |
| US20090156578A1 (en) | 2005-12-05 | 2009-06-18 | PAULS Henry | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents |
| CA2633500A1 (en) | 2005-12-20 | 2007-07-05 | President And Fellows Of Harvard College | Compounds, screens, and methods of treatment |
| GB0605689D0 (en) | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
| WO2007126871A1 (en) | 2006-03-29 | 2007-11-08 | Array Biopharma Inc. | P38 inhibitors and methods of use thereof |
| EP2032539A4 (en) | 2006-06-09 | 2011-03-16 | Merck Sharp & Dohme | BENZAZEPINONE AS SODIUM CHANNEL BLOCKER |
| EP2054422B1 (en) | 2006-07-20 | 2017-06-14 | Debiopharm International SA | Acrylamide derivatives as fab i inhibitors |
| JP5511379B2 (ja) | 2006-07-21 | 2014-06-04 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｃｇｒｐレセプターアンタゴニスト |
| US9987277B2 (en) | 2006-10-04 | 2018-06-05 | Janssen Sciences Ireland Uc | Carboxamide 4-[(4-pyridyl)amino] pryimidines for the treatment of hepatitis C |
| WO2008045484A1 (en) * | 2006-10-10 | 2008-04-17 | Amgen Inc. | N-aryl pyrazole compounds for use against diabetes |
| EP1939187A1 (en) * | 2006-12-20 | 2008-07-02 | Sanofi-Aventis | Substituted heteroaryl pyridopyrimidone derivatives |
| US20100210649A1 (en) | 2006-12-21 | 2010-08-19 | Sloan-Kettering Institute For Cancer Research | Pyridazinones and furan-containing compounds |
| US20100144715A1 (en) | 2007-02-28 | 2010-06-10 | Hoyt Scott B | Substituted Benzodiazepinones, Benzoxazepinones and Benzothiazepinones as Sodium Channel Blockers |
| WO2008135525A2 (en) | 2007-05-02 | 2008-11-13 | Boehringer Ingelheim International Gmbh | Substituted azetidines, manufacturing and use thereof as medicaments |
| WO2008156580A1 (en) | 2007-06-13 | 2008-12-24 | Merck & Co., Inc. | Triazole derivatives for treating alzheimer's disease and related conditions |
| MY148484A (en) | 2007-08-03 | 2013-04-30 | Sanofi Aventis | Caspase imaging probes |
| WO2009085256A1 (en) | 2007-12-27 | 2009-07-09 | Panacos Pharmaceuticals, Inc. | Anti-hiv compounds |
| EP2090578A1 (en) * | 2008-01-29 | 2009-08-19 | Sanofi-Aventis | Substituted arylamide diazepinopyrimidone derivatives for the treatment of neurodegenerative diseases caused by abnormal activity of GSK3-beta |
| EP2085399A1 (en) | 2008-01-29 | 2009-08-05 | Sanofi-Aventis | substituted arylamide oxazepinopyrimidone derivatives |
| JP4708443B2 (ja) * | 2008-01-31 | 2011-06-22 | トヨタ自動車株式会社 | 作動制御マップおよび白線認識装置 |
| JP2011512410A (ja) * | 2008-02-19 | 2011-04-21 | メルク・シャープ・エンド・ドーム・コーポレイション | イミダゾベンゾアゼピンｃｇｒｐ受容体アンタゴニスト |
| EP2262783A2 (en) | 2008-02-21 | 2010-12-22 | Sanofi-Aventis | Covalently binding imaging probes |
| WO2009140549A1 (en) | 2008-05-14 | 2009-11-19 | Amgen Inc. | Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer |
| US7884074B2 (en) | 2008-05-15 | 2011-02-08 | Ikaria Development Subsidiary Two, LLC | Compounds and methods for prevention and/or treatment of inflammation using the same |
| AU2009277485B2 (en) | 2008-07-28 | 2013-05-02 | Eisai R&D Management Co., Ltd. | Spiroaminodihydrothiazine derivatives |
| UY32049A (es) | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
| DE102008037790A1 (de) | 2008-08-14 | 2010-02-18 | Merck Patent Gmbh | Bicyclische Triazolderivate |
| US8088890B2 (en) | 2008-09-26 | 2012-01-03 | Fibrex Medical Research & Development Gmbh | Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition |
| AU2009303602B2 (en) | 2008-10-14 | 2012-06-14 | Sunshine Lake Pharma Co., Ltd. | Compounds and methods of use |
| WO2010077752A1 (en) | 2008-12-17 | 2010-07-08 | Merck Sharp & Dohme Corp. | Imidazolinone derivatives as cgrp receptor antagonists |
| CN102548999A (zh) | 2009-01-20 | 2012-07-04 | 山东轩竹医药科技有限公司 | 含有取代的含氮稠杂环的头孢菌素衍生物 |
| US8624063B2 (en) | 2009-06-30 | 2014-01-07 | Wisconsin Alumni Research Foundation | Non-lactone carbocyclic and heterocyclic antagonists and agonists of bacterial quorum sensing |
| CN102647904A (zh) | 2009-09-16 | 2012-08-22 | 赛林药物股份有限公司 | 新型三环蛋白激酶调节剂 |
| WO2011059839A1 (en) | 2009-10-29 | 2011-05-19 | Sirtris Pharmaceuticals, Inc. | Bicyclic pyridines and analogs as sirtuin modulators |
| US8481541B2 (en) | 2010-03-22 | 2013-07-09 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
| US20130137642A1 (en) | 2010-04-23 | 2013-05-30 | Demetrios Vavvas | Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells |
| JPWO2011142381A1 (ja) | 2010-05-11 | 2013-08-29 | 藤田 岳 | ベンゾ若しくはピリドイミダゾール誘導体 |
| KR20130122531A (ko) | 2010-05-24 | 2013-11-07 | 벤더르빌트 유니버시티 | Ｍｇｌｕｒ５ 양성 알로스테릭 조절물로서 치환된 ６메틸니코틴아미드 |
| WO2012061408A2 (en) | 2010-11-02 | 2012-05-10 | Rigel Pharmaceuticals. Inc. | Method for making macrocycles |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| UY34171A (es) | 2011-07-01 | 2013-01-31 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como moduladores del canal iónico |
| US9056877B2 (en) | 2011-07-19 | 2015-06-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| AR087107A1 (es) | 2011-07-27 | 2014-02-12 | Lilly Co Eli | Compuesto inhibidor de la señalizacion de la trayectoria notch |
| WO2013013826A1 (en) | 2011-07-27 | 2013-01-31 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Necroptosis inhibitors for the treatment of inflammatory diseases of the gastrointestinal tract |
| EP2773341A2 (en) | 2011-10-21 | 2014-09-10 | Massachusetts Eye & Ear Infirmary | Compositions comprising necrosis inhibitors, such as necrostatins, alone or in combination, for promoting axon regeneration and nerve function, thereby treating cns disorders |
| US9062075B2 (en) | 2011-12-02 | 2015-06-23 | Aurigene Discovery Technologies Limited | Tetrahydropyridine derivatives as FabI inhibitors |
| SG11201402409UA (en) | 2011-12-02 | 2014-10-30 | Aurigene Discovery Tech Ltd | Substituted pyridine derivatives as fabi inhibitors |
| US9217050B2 (en) | 2012-04-03 | 2015-12-22 | 3M Innovative Properties Company | Crosslinkable composition comprising photobase generators |
| WO2013189241A1 (zh) | 2012-06-20 | 2013-12-27 | 上海恒瑞医药有限公司 | 嘧啶二胺类衍生物、其制备方法及其在医药上的应用 |
| TWI520962B (zh) | 2012-06-29 | 2016-02-11 | 貝達藥業股份有限公司 | As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives |
| MX2015000362A (es) | 2012-07-13 | 2015-04-14 | Hoffmann La Roche | Benzo(b)-azepin-2-onas antiproliferativas. |
| RU2015105561A (ru) | 2012-08-09 | 2016-09-27 | Ф. Хоффманн-Ля Рош Аг | Замещенные гетероазепиноны |
| CN103664904A (zh) | 2012-09-07 | 2014-03-26 | 李振 | 一种γ-分泌酶抑制剂及其用途 |
| WO2014072930A2 (en) | 2012-11-09 | 2014-05-15 | Aurigene Discovery Technologies Limited | Fused pyridine derivatives as antibacterial agents |
| TWI648274B (zh) * | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 （二） |
| WO2014144547A2 (en) | 2013-03-15 | 2014-09-18 | The Regents Of The University Of California | Amide derivatives of lactam based n-acylethanolamine acid amidase (naaa) inhibitors |
| FR3003860B1 (fr) | 2013-03-29 | 2015-11-27 | Oreal | Composes derives d'iridoides proteges ou non, composition les comprenant, utilisation comme colorant des fibres keratiniques et dispositifs |
| EP2986317A4 (en) | 2013-04-15 | 2016-10-05 | Yeda Res & Dev | INHIBITION OF RIP KINASES FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES |
| WO2015027137A1 (en) | 2013-08-23 | 2015-02-26 | University Of Tennessee Research Foundation | Improved synthesis of capuramycin and its analogues |
| WO2015103583A1 (en) | 2014-01-06 | 2015-07-09 | President And Fellows Of Harvard College | Monobactams and methods of their synthesis and use |
| WO2015104677A1 (en) | 2014-01-10 | 2015-07-16 | Piramal Enterprises Limited | Heterocyclic compounds as ezh2 inhibitors |
| EP3148543B1 (en) | 2014-05-30 | 2020-04-08 | Icahn School of Medicine at Mount Sinai | Small molecule transcription modulators of bromodomains |
| US9616047B2 (en) | 2014-06-30 | 2017-04-11 | Regents Of University Of Minnesota | Inhibitors of beta-catenin in treatment of colorectal cancer |
| EP3180014A1 (en) | 2014-08-13 | 2017-06-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Prevention of tumour metastasis by inhibition of necroptosis |
| RU2017109122A (ru) | 2014-08-21 | 2018-09-21 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы |
| CN107108512B (zh) | 2014-10-10 | 2021-05-04 | 基因泰克公司 | 治疗性化合物及其用途 |
| EP3017825A1 (en) | 2014-11-06 | 2016-05-11 | Ludwig-Maximilians-Universität München | An inhibitor of the RIPK1-dependent necrosis pathway and a pharmaceutical composition comprising the same |
| WO2016101887A1 (en) | 2014-12-24 | 2016-06-30 | National Institute Of Biological Sciences, Beijing | Necrosis inhibitors |
| EP3224237B1 (en) | 2014-12-24 | 2024-09-11 | National Institute Of Biological Sciences, Beijing | Necrosis inhibitors |
| CN107001337B (zh) | 2015-01-13 | 2021-05-04 | 诺华股份有限公司 | 作为血管紧张素ii型拮抗剂的吡咯烷衍生物 |
| EP3256467A1 (en) | 2015-02-13 | 2017-12-20 | GlaxoSmithKline Intellectual Property Management Limited | Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide |
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| RU2716136C2 (ru) * | 2015-07-02 | 2020-03-06 | Ф. Хоффманн-Ля Рош Аг | Бициклические лактамы и способы их применения |
| WO2017022962A1 (ko) | 2015-07-07 | 2017-02-09 | 가톨릭대학교 산학협력단 | Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 |
| WO2017069279A1 (ja) | 2015-10-23 | 2017-04-27 | 武田薬品工業株式会社 | 複素環化合物 |
| US10961258B2 (en) | 2015-12-21 | 2021-03-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| CN107043377A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途 |
| CN107043378A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体 |
| US9815850B2 (en) | 2016-02-05 | 2017-11-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
-
2017
- 2017-02-03 US US15/424,216 patent/US9815850B2/en active Active
- 2017-02-03 CA CA3012832A patent/CA3012832A1/en active Pending
- 2017-02-03 CR CR20180413A patent/CR20180413A/es unknown
- 2017-02-03 TW TW106103687A patent/TWI781920B/zh active
- 2017-02-03 CN CN202410933273.5A patent/CN118994191A/zh active Pending
- 2017-02-03 EA EA201891620A patent/EA201891620A1/ru unknown
- 2017-02-03 TN TNP/2018/000276A patent/TN2018000276A1/en unknown
- 2017-02-03 IL IL287136A patent/IL287136B2/en unknown
- 2017-02-03 CN CN201780021671.8A patent/CN109071504B/zh active Active
- 2017-02-03 CN CN202410933271.6A patent/CN118994190A/zh active Pending
- 2017-02-03 CN CN202210159353.0A patent/CN114437105B/zh active Active
- 2017-02-03 KR KR1020187025396A patent/KR102808827B1/ko active Active
- 2017-02-03 SG SG11201806302RA patent/SG11201806302RA/en unknown
- 2017-02-03 JP JP2018541178A patent/JP6974331B2/ja active Active
- 2017-02-03 SG SG10201913587WA patent/SG10201913587WA/en unknown
- 2017-02-03 PE PE2018001382A patent/PE20181665A1/es unknown
- 2017-02-03 MA MA044007A patent/MA44007A/fr unknown
- 2017-02-03 TW TW111140232A patent/TWI836679B/zh active
- 2017-02-03 MY MYPI2018702604A patent/MY196648A/en unknown
- 2017-02-03 WO PCT/US2017/016509 patent/WO2017136727A2/en not_active Ceased
- 2017-02-03 AU AU2017213628A patent/AU2017213628B2/en active Active
- 2017-02-03 EP EP17705751.0A patent/EP3414239A2/en active Pending
- 2017-02-03 MX MX2018009448A patent/MX2018009448A/es unknown
- 2017-09-29 US US15/721,470 patent/US10131676B2/en active Active
- 2017-09-29 US US15/721,419 patent/US9896458B2/en active Active
-
2018
- 2018-07-19 IL IL260674A patent/IL260674B/en unknown
- 2018-07-25 PH PH12018501583A patent/PH12018501583A1/en unknown
- 2018-08-01 DO DO2018000175A patent/DOP2018000175A/es unknown
- 2018-08-02 MX MX2021013228A patent/MX2021013228A/es unknown
- 2018-08-02 SA SA518392146A patent/SA518392146B1/ar unknown
- 2018-08-02 MX MX2021013226A patent/MX2021013226A/es unknown
- 2018-08-02 CL CL2018002081A patent/CL2018002081A1/es unknown
- 2018-08-21 CO CONC2018/0008707A patent/CO2018008707A2/es unknown
- 2018-09-03 EC ECSENADI201866138A patent/ECSP18066138A/es unknown
- 2018-09-13 US US16/130,817 patent/US10604535B2/en active Active
-
2020
- 2020-02-05 US US16/782,446 patent/US20200317691A1/en not_active Abandoned
-
2021
- 2021-02-25 US US17/185,684 patent/US20230043400A1/en not_active Abandoned
- 2021-11-02 JP JP2021179107A patent/JP7381543B2/ja active Active
-
2023
- 2023-08-10 US US18/232,435 patent/US12358928B2/en active Active
-
2025
- 2025-06-05 US US19/229,139 patent/US20250388601A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11547704B2 (en) | Chemical compounds | |
| JP7150903B2 (ja) | Ｂ型肝炎ウイルスコアタンパク質モジュレーター | |
| JP2025031810A (ja) | 化合物、組成物、及び、方法 | |
| JP6505956B2 (ja) | ＪＡＫ阻害剤としてのピラゾロ［１，５−ａ］ピラジン−４−イル誘導体 | |
| AU2018202865B2 (en) | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | |
| US20090069288A1 (en) | Novel therapeutic compounds | |
| US10851053B2 (en) | Chemical compounds | |
| AU2017315863C1 (en) | Substituted pyrrolizine compounds and uses thereof | |
| CA3066328A1 (en) | Chemical compounds as atf4 pathway inhibitors | |
| JP2020525512A (ja) | 癌および他の疾患を処置するためのＡＴＦ４阻害剤としての２−（４−クロロフェノキシ）−Ｎ−（（１−（２−（４−クロロフェノキシ）エチンアゼチジン（ｅｔｈｙｎａｚｅｔｉｄｉｎ）−３−イル）メチル）アセトアミド誘導体および関連化合物 | |
| US11274090B2 (en) | P300/CBP HAT inhibitors | |
| US20100249096A1 (en) | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases | |
| EP3649106A1 (en) | N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-2-cyclobutane-1-carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases | |
| CA3012832A1 (en) | N-azepinyl-carboxamide inhibitors of receptor-interacting protein kinase1 | |
| CN102834382A (zh) | 作为钙释放激活钙通道调节剂的吡唑衍生物 | |
| CZ297907B6 (cs) | Aminothiazolové deriváty a farmaceutické kompozice s jejich obsahem | |
| CA2660031A1 (en) | Pyrazole derivatives as cytochrome p450 inhibitors | |
| KR20110044782A (ko) | 아제티딘 다치환된 화합물, 그의 제조법 및 그의 치료 용도 | |
| CN104520298B (zh) | 用于治疗脆性x染色体综合征、帕金森病或返流疾病的二吖庚因酮衍生物 | |
| US20250109128A1 (en) | C-myc mrna translation modulators and uses thereof in the treatment of cancer | |
| CN113727756A (zh) | P300/cbp hat抑制剂和其使用方法 | |
| US20210093619A1 (en) | Chemical Compounds as ATF-4 Pathway Inhibitors | |
| CN115484954A (zh) | Irak1的有效和选择性不可逆抑制剂 | |
| RU2024115831A (ru) | Изоксазолидины в качестве ингибиторов ripk1 и их применение | |
| HK1157748A (en) | Azetidine polysubstituted compounds, preparation thereof, and therapeutic application thereof |